glp-1 news november 6 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 trends 2025: real-world data,

The transition typically involves: Matching equivalent doses between formulations and medications Monitoring blood sugar levels during the switch Maintaining consistent injection schedules Your provider might recommend evidence-based nutrition counseling or programs to support your transition and maximize results

The higher-dose semaglutide formulation for obesity (Wegovy, 2.4 mg weekly) can produce 10-15% weight loss, while diabetes doses typically yield more modest reductions

[DOI] [PMC free article] [PubMed] [Google Scholar] 178.de Iuliis A., Montinaro E., Fatati G., Plebani M., Colosimo C

significant weight reduction (~ 710%) through calorie restriction, with or without exercise, and bariatric/metabolic surgery results in high turnover bone loss

This dual-sourcing approach is becoming more common, particularly for programmes where continuity of supply is critical